Cargando…

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study

AIMS/HYPOTHESIS: Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jie, Xu, Min, Walker, Venexia, Yuan, Jinqiu, Korologou-Linden, Roxanna, Robinson, Jamie, Huang, Peiyuan, Burgess, Stephen, Au Yeung, Shiu Lun, Luo, Shan, Holmes, Michael V., Davey Smith, George, Ning, Guang, Wang, Weiqing, Gaunt, Tom R., Bi, Yufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477943/
https://www.ncbi.nlm.nih.gov/pubmed/35902387
http://dx.doi.org/10.1007/s00125-022-05743-0
_version_ 1784790473056976896
author Zheng, Jie
Xu, Min
Walker, Venexia
Yuan, Jinqiu
Korologou-Linden, Roxanna
Robinson, Jamie
Huang, Peiyuan
Burgess, Stephen
Au Yeung, Shiu Lun
Luo, Shan
Holmes, Michael V.
Davey Smith, George
Ning, Guang
Wang, Weiqing
Gaunt, Tom R.
Bi, Yufang
author_facet Zheng, Jie
Xu, Min
Walker, Venexia
Yuan, Jinqiu
Korologou-Linden, Roxanna
Robinson, Jamie
Huang, Peiyuan
Burgess, Stephen
Au Yeung, Shiu Lun
Luo, Shan
Holmes, Michael V.
Davey Smith, George
Ning, Guang
Wang, Weiqing
Gaunt, Tom R.
Bi, Yufang
author_sort Zheng, Jie
collection PubMed
description AIMS/HYPOTHESIS: Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease and potential causal mechanisms in the brain linking the two. METHODS: Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA(1c) level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising 527,138 middle-aged Europeans, including 71,880 with Alzheimer’s disease or Alzheimer’s disease-by-proxy. MR estimates representing lifelong metformin use on Alzheimer’s disease and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6601 donors) on Alzheimer’s disease was further estimated. RESULTS: Genetically proxied metformin use, equivalent to a 6.75 mmol/mol (1.09%) reduction on HbA(1c), was associated with 4% lower odds of Alzheimer’s disease (OR 0.96 [95% CI 0.95, 0.98], p=1.06×10(−4)) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on Alzheimer’s disease (OR 0.88, p=4.73×10(−4)) that was independent of AMP-activated protein kinase. MR of expression in brain cortex tissue showed that decreased MCI-related gene (NDUFA2) expression was associated with lower Alzheimer’s disease risk (OR 0.95, p=4.64×10(−4)) and favourable cognitive function. CONCLUSIONS/INTERPRETATION: Metformin use may cause reduced Alzheimer’s disease risk in the general population. Mitochondrial function and the NDUFA2 gene are plausible mechanisms of action in dementia protection. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05743-0) contains peer-reviewed but unedited supplementary material..
format Online
Article
Text
id pubmed-9477943
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94779432022-09-17 Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study Zheng, Jie Xu, Min Walker, Venexia Yuan, Jinqiu Korologou-Linden, Roxanna Robinson, Jamie Huang, Peiyuan Burgess, Stephen Au Yeung, Shiu Lun Luo, Shan Holmes, Michael V. Davey Smith, George Ning, Guang Wang, Weiqing Gaunt, Tom R. Bi, Yufang Diabetologia Article AIMS/HYPOTHESIS: Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease and potential causal mechanisms in the brain linking the two. METHODS: Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA(1c) level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising 527,138 middle-aged Europeans, including 71,880 with Alzheimer’s disease or Alzheimer’s disease-by-proxy. MR estimates representing lifelong metformin use on Alzheimer’s disease and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6601 donors) on Alzheimer’s disease was further estimated. RESULTS: Genetically proxied metformin use, equivalent to a 6.75 mmol/mol (1.09%) reduction on HbA(1c), was associated with 4% lower odds of Alzheimer’s disease (OR 0.96 [95% CI 0.95, 0.98], p=1.06×10(−4)) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on Alzheimer’s disease (OR 0.88, p=4.73×10(−4)) that was independent of AMP-activated protein kinase. MR of expression in brain cortex tissue showed that decreased MCI-related gene (NDUFA2) expression was associated with lower Alzheimer’s disease risk (OR 0.95, p=4.64×10(−4)) and favourable cognitive function. CONCLUSIONS/INTERPRETATION: Metformin use may cause reduced Alzheimer’s disease risk in the general population. Mitochondrial function and the NDUFA2 gene are plausible mechanisms of action in dementia protection. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05743-0) contains peer-reviewed but unedited supplementary material.. Springer Berlin Heidelberg 2022-07-29 2022 /pmc/articles/PMC9477943/ /pubmed/35902387 http://dx.doi.org/10.1007/s00125-022-05743-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zheng, Jie
Xu, Min
Walker, Venexia
Yuan, Jinqiu
Korologou-Linden, Roxanna
Robinson, Jamie
Huang, Peiyuan
Burgess, Stephen
Au Yeung, Shiu Lun
Luo, Shan
Holmes, Michael V.
Davey Smith, George
Ning, Guang
Wang, Weiqing
Gaunt, Tom R.
Bi, Yufang
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
title Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
title_full Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
title_fullStr Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
title_full_unstemmed Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
title_short Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
title_sort evaluating the efficacy and mechanism of metformin targets on reducing alzheimer’s disease risk in the general population: a mendelian randomisation study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477943/
https://www.ncbi.nlm.nih.gov/pubmed/35902387
http://dx.doi.org/10.1007/s00125-022-05743-0
work_keys_str_mv AT zhengjie evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT xumin evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT walkervenexia evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT yuanjinqiu evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT korologoulindenroxanna evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT robinsonjamie evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT huangpeiyuan evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT burgessstephen evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT auyeungshiulun evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT luoshan evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT holmesmichaelv evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT daveysmithgeorge evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT ningguang evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT wangweiqing evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT gaunttomr evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy
AT biyufang evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy